Cardona QRA, Mejía PGS, López LL, Álvarez HLF, Ruiz MC, Jaramillo JLI, Villegas ÁJD, Herrera AL, Hernández RF, Martínez SLM

Language: Spanish
References: 17
Page: 1-14
PDF size: 441.67 Kb.

ABSTRACT

Introduction: The minimal residual disease is the permanence of residual leukemic cells at subclinical levels after remission of the disease. This condition increases the risk of relapse and mortality.
Objective: To characterize the clinical and molecular factors of patients with acute leukemias and minimal residual disease detected by flow cytometry in a highly complex institution in the city of Medellín, Colombia during the years 2015 - 2017.
Methodology: This is a retrospective descriptive observational study, which included patients with leukemia diagnosed by flow cytometry. A non-probabilistic sampling of consecutive cases was carried out. The information collected was entered into a database in Excel, and the analysis was carried out through the IBM SPSS Version 24 program, using absolute and relative frequencies, average and standard deviation or median and interquartile ranges, according to the nature of each variable and its distribution.
Results: 60 patients were included in which male sex predominated with 63.3% (38). The most frequent diagnosis was lymphoid leukemia with 78.3% (47). Of the total patients included, 36.6% (22) were positive for minimal residual disease; 28.3% received a bone marrow transplant and 10% (6) had a cerebrospinal fluid compromise. In the second cytometry of the patients with minimal residual disease, 90.9% (20) expressed CD45 +. 31.8% (7) of the patients with minimal residual disease relapsed.
Conclusion: Minimal residual disease is a frequent pathology in patients with acute leukemias that requires follow-up and constitutes a relevant prognostic factor.

REFERENCES

1. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, et al. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017;123(3):426-35. DOI: https://10.1002/cncr.30361

2. Short NJ, Ravandi F. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? Haematological. 2019. DOI: https://10.3324/haematol.2018.208454

3. Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, et al. Minimal residual disease prior to allogeneic hematopoietic celltransplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102(5):865-73. DOI: https://10.3324/haematol.2016.159343

4. Tembhare PR, Subramanian Pg PG, Ghogale S, Chatterjee G, Patkar NV, Gupta A,Et al. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10(6) and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients. Cytometry Part B 2019;00B: 1-11. DOI: https://10.1002/cyto.b.21831

5. Cárdenas-Araujo D, Gutiérrez-Aguirre CH. Métodos para detectar enfermedad mínima residual en leucemia linfoblástica aguda y su aplicación clínica. Hematol Méx. 2018;19(1):41-9.

6. Soria M, Gailliard M, Gutierrez M, Morán L, Rivas F, Prada S, et al. Enfermedad Mínima Residual por Citometría de Flujo en niños con Leucemia Linfoblástica Aguda. Hematol Méx. 2012; 16(1):42-6.

7. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblasticleukemia: implications for residual disease detection: a report from the children's oncology group. Cytometry 2005;68:18-24.

8. Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, et al. Drug induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia. 2005;19:49-56.

9. Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia. 2007;21:622-6.

10. Campana D. Minimal residual disease studies in acute leukemia. Am J Clin Pathol. 2004;122 Suppl:S47-57.

11. van derVelden VH, Boeckx N, van Wering ER, van Dongen JJ. Detection of minimal residual disease in acute leukemia. J Biol Reg Homeost Agents. 2004;18:146-54.

12. Campana D, Coustan-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol. 2004;112:8-15

13. Liu J, Zhao XS, Liu YR, Xu LP, Zhang XH, et al. Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Chin Med J (Engl). 2018;131(23):2808-16. DOI: https://10.4103/0366-6999.246072

14. Pérez A, Prada-Arismendy J, Castillo E, Castellanos W. Detección del gen fusión PML-RARa en pacientes colombianos con leucemia mieloide aguda. CES Medicina. 2019;33(2):88-99.

15. Olsson L, Lundin-Ström KB, Castor A, Improved cytogenetic characterization and risk stratification of pediatric acute lymphoblastic leukemia using single nucleotide polymorphism array analysis: A single center experience of 296 cases. Genes Chromosomes Cancer.2018; 1-4. DOI: https://doi.org/10.1002/gcc.22664

16. Karawajew L, Dworzak M, Ratei R, Rhein P, Gaipa G, Buldini B, et al. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Haematologica. 2015;100(7):935-44. DOI: https://10.3324/haematol.2014.116707

17. Villarroel LVR. Leucemia linfoblástica aguda B, correlación entre enfermedad mínima residual y recaída medular en pacientes pediátricos. Instituto Oncológico Nacional Solca 2015-2017. [Internet]. [acceso 15/01/2020]. (Tesis para el título de Especialista en Anatomía Patológica). Guayaquil: Universidad de Guayaquil; 2017. Disponible en: http://repositorio.ug.edu.ec/handle/redug/29349